Search - tctmd.com

Displaying 101 - 120 of 120

Sort: Relevancy | Date

News Conference News ESC 2016

Use of Antithrombotics Instead of Stents Appears Safe, Reduces Thrombus Burden in Subset of ACS Patients: EROSION

Michael O'Riordan

August 30, 2016

News Daily News

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

Michael O'Riordan

June 28, 2016

News Daily News

Updated US Guidelines Lower DAPT Duration From 12 to 6 Months in Stable Patients Receiving DES

Yael L. Maxwell

March 30, 2016

News Daily News

Las Últimas Directrices Norteamericanas Reducen la Duración del Tratamiento Antiplaquetario Doble de 12 a 6 Meses en Pacientes Estables que Reciben un SLF

Yael L. Maxwell

March 30, 2016

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Daily News

元分析解释了不同DAPT时间长短的影响

Caitlin E. Cox

April 03, 2015

News Daily News

Un Meta Análisis Arrojan Luz sobre el Impacto de la Duración del Tratamiento Antiplaquetario Doble

Caitlin E. Cox

April 03, 2015

News Daily News

Meta-analyses Shed Light on the Impact of DAPT Duration

Caitlin E. Cox

April 03, 2015

News Daily News

Short-term DAPT After DES Decreases Bleeding with No Increase in Death, MI

May 20, 2014

News Daily News

La Terapia Antiplaquetaria Doble a Corto Plazo Post-Implantación de SLF Reduce las Hemorragias Sin un Aumento de Muerte ni IM

May 20, 2014

News Daily News

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

May 14, 2014

News Daily News

Extended Dual Antiplatelet Therapy Lowers Death, MI Rates in DES Patients

Jason Kahn

December 05, 2012

News Conference News

Long-term Antiplatelet Therapy: All Risk, No Benefit

August 30, 2011

News Daily News

Details on Clopidogrel Discontinuation Remain Elusive, Unclear

L.A. McKeown

August 05, 2011

News Daily News

After GRAVITAS: Is There a Future for Functional Platelet Testing?

July 18, 2011

News Daily News

One-Month Platelet Reactivity After PCI Key Risk Factor for Future Events

June 13, 2011

News Daily News

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

L.A. McKeown

June 03, 2011

News Conference News

EXCELLENT Outcomes Regardless of Antiplatelet Therapy Duration After DES

Caitlin E. Cox

April 05, 2011

News Daily News

Dabigatran Recommended as Alternative to Warfarin in A-fib Patients

Jason Kahn

February 13, 2011

News Daily News

Prasugrel Inhibits Platelet Function Better Than High-Dose Clopidogrel in Diabetics

Jason Kahn

January 26, 2011

Advertisement

Use of Antithrombotics Instead of Stents Appears Safe, Reduces Thrombus Burden in Subset of ACS Patients: EROSION

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

Updated US Guidelines Lower DAPT Duration From 12 to 6 Months in Stable Patients Receiving DES

Las Últimas Directrices Norteamericanas Reducen la Duración del Tratamiento Antiplaquetario Doble de 12 a 6 Meses en Pacientes Estables que Reciben un SLF

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

元分析解释了不同DAPT时间长短的影响

Un Meta Análisis Arrojan Luz sobre el Impacto de la Duración del Tratamiento Antiplaquetario Doble

Meta-analyses Shed Light on the Impact of DAPT Duration

Short-term DAPT After DES Decreases Bleeding with No Increase in Death, MI

La Terapia Antiplaquetaria Doble a Corto Plazo Post-Implantación de SLF Reduce las Hemorragias Sin un Aumento de Muerte ni IM

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

Extended Dual Antiplatelet Therapy Lowers Death, MI Rates in DES Patients

Long-term Antiplatelet Therapy: All Risk, No Benefit

Details on Clopidogrel Discontinuation Remain Elusive, Unclear

After GRAVITAS: Is There a Future for Functional Platelet Testing?

One-Month Platelet Reactivity After PCI Key Risk Factor for Future Events

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

EXCELLENT Outcomes Regardless of Antiplatelet Therapy Duration After DES

Dabigatran Recommended as Alternative to Warfarin in A-fib Patients

Prasugrel Inhibits Platelet Function Better Than High-Dose Clopidogrel in Diabetics

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content